4 ms·
Um, what? Pharma continue to throw billions at AD therapy.
by neuro_imager 11y ago
Um, what?
Pharma continue to throw billions at AD therapy.
- danieltillett 11y agoFrom my understanding only one one major (Eli Lilly) now has a serious AD program - all the others have effectively walked away after losing tens of billions [1]. I have to say that Biogen’s antibody [2] is looking interesting. If I had to invest my own money in AD I would spend it on better early detection/sub-population classification and then on developing monoclonal antibodies targeting each sub-population. 1. http://pipeline.corante.com/archives/2014/01/23/alzheimers_therapies_a_reasonably_gloomy_update.php http://pipeline.corante.com/archives/2014/01/23/alzheimers_t... 2. http://pipeline.corante.com/archives/2015/03/20/biogens_alzheimers_data.php http://pipeline.corante.com/archives/2015/03/20/biogens_alzh...
- neuro_imager 11y agoThank you for this. Really interesting blog, hadn't seen it before. I can vouch for the fact that at least two other majors continue to invest heavily in AD diagnostics and/or therapeutics. You're right though that all have thrown a ton of money at this without much ROI yet (apart from those producing diagnostic radio-pharmaceuticals).